Loading...
XKRX
174900
Market cap142mUSD
Jun 12, Last price  
12,760.00KRW
Name

AbClon Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
83.72
EPS
Div Yield, %
Shrs. gr., 5y
3.54%
Rev. gr., 5y
-30.45%
Revenues
2.34b
-24.10%
14,375,025,2802,771,179,1903,018,054,1203,406,445,7303,082,804,3102,339,823,660
Net income
-16.30b
L+27.70%
2,566,574,770-6,444,953,020-10,237,783,900-9,253,793,540-12,765,642,500-16,301,551,970
CFO
-14.39b
L+51.78%
-449,877,210-5,648,350,340-8,642,823,410-7,491,983,550-9,483,894,490-14,394,378,080

Profile

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.
IPO date
Sep 18, 2017
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
2,339,824
-24.10%
3,082,804
-9.50%
3,406,446
12.87%
Cost of revenue
15,568,428
12,437,243
10,428,101
Unusual Expense (Income)
NOPBT
(13,228,604)
(9,354,439)
(7,021,656)
NOPBT Margin
Operating Taxes
10,953
(1,095,307)
Tax Rate
NOPAT
(13,228,604)
(9,365,392)
(5,926,349)
Net income
(16,301,552)
27.70%
(12,765,642)
37.95%
(9,253,794)
-9.61%
Dividends
Dividend yield
Proceeds from repurchase of equity
17,000
85,000
70,000
BB yield
-0.01%
-0.04%
-0.04%
Debt
Debt current
17,241,934
12,576,191
7,149,341
Long-term debt
160,062
100,423
4,807,889
Deferred revenue
Other long-term liabilities
660,957
565,226
4,094,829
Net debt
(4,460,928)
(4,821,460)
(12,182,337)
Cash flow
Cash from operating activities
(14,394,378)
(9,483,894)
(7,491,984)
CAPEX
(166,858)
(45,942)
(89,707)
Cash from investing activities
2,074,751
13,551,153
(9,463,441)
Cash from financing activities
18,843,263
2,891,814
21,486,164
FCF
(12,638,292)
(7,683,521)
(15,750,295)
Balance
Cash
21,862,924
17,498,074
24,139,567
Long term investments
Excess cash
21,745,933
17,343,934
23,969,245
Stockholders' equity
(63,728,457)
(48,167,733)
(24,633,613)
Invested Capital
111,046,403
88,566,295
77,091,250
ROIC
ROCE
EV
Common stock shares outstanding
17,303
15,365
15,121
Price
14,120.00
-4.72%
14,820.00
15.78%
12,800.00
-27.68%
Market cap
244,316,849
7.30%
227,705,625
17.65%
193,543,398
-28.44%
EV
240,298,002
223,527,611
181,955,415
EBITDA
(11,638,011)
(7,670,183)
(5,504,576)
EV/EBITDA
Interest
900,057
1,350,399
489,586
Interest/NOPBT